Efficacy of Ventavis Used in Real-life Setting.

• Status: Completed
• Trial end date: 2016-09-22
• Target enrollment: 0
• Participant gender: All

Summary

This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis.

Typical clinical measures and quality of life will be prospectively followed in 12 months period.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Iloprost

Criteria

Inclusion Criteria:

• Pulmonary arterial hypertension in WHO functional class III or IV

• Age 18+

• Patients newly treated with Ventavis or switched from sildenafil

Exclusion Criteria:

• Retrospective documentation is not allowed